The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2 ...

Announcing a new article publication for BIO Integration journal. Bladder cancer (BLCA) is one of the most common malignancies and the second most frequent urogenital tract tumor.

A team of scientists has uncovered the remarkable potential of a human antibody, mAb 3A6, in fighting Ebola virus infections.

Many patent applicants currently face difficulty in obtaining antibody claims because of written description and enablement ...

In in vitro and in vivo preclinical studies, ficerafusp alfa + a KRAS-G12C inhibitor (G12Ci) was shown to be more effective than G12Ci alone, with G12Ci-resistant lung cancer cells remaining ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

This study highlights the promising potential of LC–MS as a powerful tool for mAb quality control within the context of upstream processing.

The data, presented in a poster titled "AP402, a bispecific antibody targeting p95HER2 and CD137, shows potent antitumor activity," highlight the therapeutic potential of AP402 to address ...

Boehringer Ingelheim’s drug candidate for human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer ...

Bicara Therapeutics Inc.’s BCAX share price has dipped by 6.53%, which has investors questioning if this is right time to buy ...

Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing ...